Unknown

Dataset Information

0

IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis.


ABSTRACT:

Background

Tumor necrosis factor (TNF) blockers have a high efficacy in treating Ankylosing Spondylitis (AS), yet up to 40% of AS patients show poor or even no response to this treatment. In this paper, we aim to build an approach to predict the response prior to clinical treatment.

Methods

AS patients during the active progression were included and treated with TNF blocker for 3 months. Patients who do not fulfill ASASAS40 were considered as poor responders. The Immunoglobulin G galactosylation (IgG-Gal) ratio representing the quantity of IgG galactosylation was calculated and candidate single nucleotide polymorphisms (SNPs) in patients treated with etanercept was obtained. Machine-learning models and cross-validation were conducted to predict responsiveness.

Results

Both IgG-Gal ratio at each time point and differential IgG-Gal ratios between week 0 and weeks 2, 4, 8, 12 showed significant difference between responders and poor-responders. Area under curve (AUC) of the IgG-Gal ratio prediction model was 0.8 after cross-validation, significantly higher than current clinical indexes (C-reactive protein (CRP) = 0.65, erythrocyte sedimentation rate (ESR) = 0.59). The SNP MYOM2-rs2294066 was found to be significantly associated with responsiveness of etanercept treatment. A three-stage approach consisting of baseline IgG-Gal ratio, differential IgG-Gal ratio in 2 weeks, and rs2294066 genotype demonstrated the ability to precisely predict the response of anti-TNF therapy (100% for poor-responders, 98% for responders).

Conclusions

Combination of different omics can more precisely to predict the response of TNF blocker and it is potential to be applied clinically in the future.

SUBMITTER: Liu J 

PROVIDER: S-EPMC6567531 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis.

Liu Jing J   Zhu Qi Q   Han Jing J   Zhang Hui H   Li Yuan Y   Ma Yanyun Y   He Dongyi D   Gu Jianxin J   Zhou Xiaodong X   Reveille John D JD   Jin Li L   Zou Hejian H   Ren Shifang S   Wang Jiucun J  

Molecular medicine (Cambridge, Mass.) 20190613 1


<h4>Background</h4>Tumor necrosis factor (TNF) blockers have a high efficacy in treating Ankylosing Spondylitis (AS), yet up to 40% of AS patients show poor or even no response to this treatment. In this paper, we aim to build an approach to predict the response prior to clinical treatment.<h4>Methods</h4>AS patients during the active progression were included and treated with TNF blocker for 3 months. Patients who do not fulfill ASASAS40 were considered as poor responders. The Immunoglobulin G  ...[more]

Similar Datasets

| S-EPMC10483821 | biostudies-literature
| S-EPMC9351697 | biostudies-literature
| S-EPMC5315003 | biostudies-literature
| S-EPMC5549282 | biostudies-other
| S-EPMC6123474 | biostudies-literature
| S-EPMC8709566 | biostudies-literature
| S-EPMC7933516 | biostudies-literature
| S-EPMC7741170 | biostudies-literature
| S-EPMC9960917 | biostudies-literature
| S-EPMC10060776 | biostudies-literature